To require the Secretary of Health and Human Services to approve a risk evaluation and mitigation strategy for mifepristone that is identical to the strategy previously approved, and for other purposes.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill adds or tightens a compliance mandate provision: 3. Mifepristone REMS, expands a appropriation, compliance mandate, trade restriction provision: 4, and adds or tightens a trade restriction provision: 5. Ban on importation Section 801 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 381) is amended— in the third sentence of subsection (a), by inserting or is. It relies on compliance mandates, trade restrictions, and appropriations. The main policy areas are Healthcare.
Who Benefits and How
The available clause analysis does not identify a specific beneficiary group.
Who Bears the Burden and How
No clear private burden is identified from the available clause analysis; implementing agencies may still take on administrative work.
Key Provisions
- Adds or tightens a compliance mandate provision: 3. Mifepristone REMS.
- Expands a appropriation, compliance mandate, trade restriction provision: 4.
- Adds or tightens a trade restriction provision: 5. Ban on importation Section 801 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 381) is amended— in the third sentence of subsection (a), by inserting or is...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for primary purpose and policy domains.
At a Glance
What This Bill Does
The bill adds or tightens a compliance mandate provision: 3. Mifepristone REMS, expands a appropriation, compliance mandate, trade restriction provision: 4, and adds or tightens a trade restriction provision: 5. Ban on importation Section 801 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 381) is amended— in the third sentence of subsection (a), by inserting or is.
Key Policy Areas
Healthcare
Primary Purpose
The bill adds or tightens a compliance mandate provision: 3. Mifepristone REMS, expands a appropriation, compliance mandate, trade restriction provision: 4, and adds or tightens a trade restriction provision: 5. Ban on importation Section 801 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 381) is amended— in the third sentence of subsection (a), by inserting or is.
Policy Domains
Sponsors
Legislative Progress
IntroducedMr. Hawley introduced the following bill; which was read twice …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "secretary_of_health_and_human_services"
- → Secretary of Health and Human Services
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology